Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: A retrospective cohort study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Choe, Ji Young ^a   Yun, Ji Y ^a   Jeon, Yoon K ^b   Kim, Se H ^c   Park, Gyeongsin ^d   Huh, Joo R ^e   Oh, Sohee ^f   Kim, Ji E ^f  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Asan Medical Center   (South Korea)

^f Seoul National University Boramae Hospital   (South Korea)

Author keywords

Epstein barr virus infections; Hodgkin disease; Indoleamine pyrrole 2,3 dioxygenase; Macrophages; Pathology; Stromal cells; Tumor microenvironment

Indexed keywords

CD163 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL INFILTRATION; CLINICAL FEATURE; COHORT ANALYSIS; DENDRITIC CELL; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HISTIOCYTE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PATHOLOGY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STROMA CELL; SURVIVAL; TUMOR CELL; TUMOR MICROENVIRONMENT; ADOLESCENT; AGED; BIOPSY; CELL LINEAGE; CHILD; DISEASE FREE SURVIVAL; ENZYMOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CELL LINEAGE; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROMAL CELLS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84901239041     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-335     Document Type: Article

References (21)

1. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent?. Leukemia 2008, 22:49-58. 10.1038/sj.leu.2404970, 17914412.
2. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011, 29:1812-1826. 10.1200/JCO.2010.32.8401, 21483001.
3. Wilke CM, Zou W. T lymphocytes to IDO + cells: check. Blood 2011, 117:2082-2083. 10.1182/blood-2010-12-322172, 21330479.
4. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009, 113:2394-2401. 10.1182/blood-2008-07-144485, 19023117.
5. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007, 7:817-823. 10.1038/nri2163, 17767193.
6. Andersen MH. The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase. Cancer Immunol Immunother 2012, 61:1289-1297. 10.1007/s00262-012-1234-4, 3401509, 22388712.
7. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011, 17:6985-6991. 10.1158/1078-0432.CCR-11-1331, 22068654.
8. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008, 14:2310-2317. 10.1158/1078-0432.CCR-07-4144, 18413819.
9. Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009, 115:185-192. 10.1016/j.ygyno.2009.07.015, 19665763.
10. Lee JR. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003, 83:1457-1466. 10.1097/01.LAB.0000090158.68852.D1, 14563947.
11. Ninomiya S, Hara T, Tsurumi H, Hoshi M, Kanemura N, Goto N, Kasahara S, Shimizu M, Ito H, Saito K, Hirose Y, Yamada T, Takahashi T, Seishima M, Takami T, Moriwaki H. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011, 90:409-416. 10.1007/s00277-010-1093-z, 20938662.
12. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885. 10.1056/NEJMoa0905680, 2897174, 20220182.
13. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, D'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011, 96:269-276. 10.3324/haematol.2010.031542, 3031695, 21071500.
14. Zaki MA, Wada N, Ikeda J, Shibayama H, Hashimoto K, Yamagami T, Tatsumi Y, Tsukaguchi M, Take H, Tsudo M, Morii E, Aozasa K. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011, 459:361-366. 10.1007/s00428-011-1140-8, 21874508.
15. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010, 77:301-308. 10.1159/000321567, 21266828.
16. Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA, Calaminici M, Gribben JG. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013, 31:256-262. 10.1200/JCO.2011.39.9881, 23045593.
17. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4 + CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 2007, 178:6840-6848. 10.4049/jimmunol.178.11.6840, 17513732.
18. Koh YW, Yoon DH, Suh C, Huh J. Impact of the Epstein-Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea. Ann Hematol 2012, 91:1403-1412. 10.1007/s00277-012-1464-8, 22526365.
19. Kennedy-Nasser AA, Hanley P, Bollard CM. Hodgkin disease and the role of the immune system. Pediatr Hematol Oncol 2011, 28:176-186. 3168532, 21381869.
20. Song H, Park H, Kim J, Park G, Kim YS, Kim SM, Kim D, Seo SK, Lee HK, Cho D, Hur D. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol Lett 2011, 136:187-193. 10.1016/j.imlet.2011.01.009, 21277902.
21. Manches O, Fernandez MV, Plumas J, Chaperot L, Bhardwaj N. Activation of the noncanonical NF-kappaB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc Natl Acad Sci U S A 2012, 109:14122-14127. 10.1073/pnas.1204032109, 3435221, 22879398.